ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2025
Defining critical symptom parameters for an ePRO-based management pathway during systemic treatment for advanced upper gastrointestinal cancer: a longitudinal study.
Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeEstablishing a care pathway based on electronic patient-reported outcomes (ePROs) is necessary to effectively assess and manage outpatients undergoing active treatment. This study investigated symptom burden in patients with advanced upper gastrointestinal (UGI) cancer and the characteristics needed for implementing an ePRO system to monitor these patients.
methodsPatients undergoing systemic therapy for metastatic UGI cancer rated symptom severity and functional impairment by completing the MD Anderson Symptom Inventory for Gastrointestinal Cancer (MDASI-GI) repeatedly for 12 months. Group-based trajectory analysis classified patients into a high-severity symptom group if their symptoms were consistently rated higher than other patients' symptoms over time. A composite score of the most-severe symptoms was calculated and evaluated.
resultsOf 111 enrollees, 92 patients (esophageal, 35%; gastroesophageal junction, 25%; gastric, 40%) provided PRO data at baseline plus at least the first 2 weeks of treatment. More than 55% of patients were in the high-severity group for fatigue, lack of appetite, numbness/tingling, and drowsiness, and more than 33% were in the high-severity symptom for inability to eat, nausea, pain, and disturbed sleep. A composite score of these 8 symptoms (45% in the high-severity symptom group; mean 4.5, median 4.4) was associated with poorer quality of life.
conclusionIn this real-world longitudinal study, 45% of patients with advanced UGI reported 8 disease- or treatment-specific symptoms that were persistently more severe over time. This provides a rationale for implementing ePRO-based routine assessment and management of this patient cohort during systemic therapy, especially during the first 12 weeks of treatment.
Indexed as
Identifiers
41071443What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.